These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 38553905)

  • 1. Frequency of Fusion Inhibitor Resistance Mutations Among Therapy-Naïve HIV Patients.
    Ghassabi F; Hashempour A; Dehghani B; Hasanshahi Z; Khodadad N; Behizadeh F; Davarpanah MA
    AIDS Res Hum Retroviruses; 2024 Aug; 40(8):471-481. PubMed ID: 38553905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Performance of human immunodeficiency virus type 1 gp41 assays for detecting enfuvirtide (T-20) resistance mutations.
    Marcial M; Lu J; Deeks SG; Ziermann R; Kuritzkes DR
    J Clin Microbiol; 2006 Sep; 44(9):3384-7. PubMed ID: 16954280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural and Functional Characterization of the Secondary Mutation N126K Selected by Various HIV-1 Fusion Inhibitors.
    Yu D; Su Y; Ding X; Zhu Y; Qin B; Chong H; Cui S; He Y
    Viruses; 2020 Mar; 12(3):. PubMed ID: 32197300
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutations of Glu560 within HIV-1 Envelope Glycoprotein N-terminal heptad repeat region contribute to resistance to peptide inhibitors of virus entry.
    Yuan C; Wang JY; Zhao HJ; Li Y; Li D; Ling H; Zhuang M
    Retrovirology; 2019 Dec; 16(1):36. PubMed ID: 31796053
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular mechanism of HIV-1 resistance to sifuvirtide, a clinical trial-approved membrane fusion inhibitor.
    Yu D; Ding X; Liu Z; Wu X; Zhu Y; Wei H; Chong H; Cui S; He Y
    J Biol Chem; 2018 Aug; 293(33):12703-12718. PubMed ID: 29929981
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of human immunodeficiency virus type 1 gp41 amino acid substitutions selected during enfuvirtide treatment on gp41 binding and antiviral potency of enfuvirtide in vitro.
    Mink M; Mosier SM; Janumpalli S; Davison D; Jin L; Melby T; Sista P; Erickson J; Lambert D; Stanfield-Oakley SA; Salgo M; Cammack N; Matthews T; Greenberg ML
    J Virol; 2005 Oct; 79(19):12447-54. PubMed ID: 16160172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutations That Increase the Stability of the Postfusion gp41 Conformation of the HIV-1 Envelope Glycoprotein Are Selected by both an X4 and R5 HIV-1 Virus To Escape Fusion Inhibitors Corresponding to Heptad Repeat 1 of gp41, but the gp120 Adaptive Mutations Differ between the Two Viruses.
    Zhuang M; Vassell R; Yuan C; Keller PW; Ling H; Wang W; Weiss CD
    J Virol; 2019 Jun; 93(11):. PubMed ID: 30894471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Specific mutations in HIV-1 gp41 are associated with immunological success in HIV-1-infected patients receiving enfuvirtide treatment.
    Aquaro S; D'Arrigo R; Svicher V; Perri GD; Caputo SL; Visco-Comandini U; Santoro M; Bertoli A; Mazzotta F; Bonora S; Tozzi V; Bellagamba R; Zaccarelli M; Narciso P; Antinori A; Perno CF
    J Antimicrob Chemother; 2006 Oct; 58(4):714-22. PubMed ID: 16891628
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment with the fusion inhibitor enfuvirtide influences the appearance of mutations in the human immunodeficiency virus type 1 regulatory protein rev.
    Svicher V; Alteri C; D'Arrigo R; Laganà A; Trignetti M; Lo Caputo S; Callegaro AP; Maggiolo F; Mazzotta F; Ferro A; Dimonte S; Aquaro S; di Perri G; Bonora S; Tommasi C; Trotta MP; Narciso P; Antinori A; Perno CF; Ceccherini-Silberstein F
    Antimicrob Agents Chemother; 2009 Jul; 53(7):2816-23. PubMed ID: 19124665
    [TBL] [Abstract][Full Text] [Related]  

  • 10. gp41 sequence variability in HIV type 1 non-B subtypes infected patients undergoing enfuvirtide pressure.
    D'Arrigo R; Ciccozzi M; Gori C; Montieri S; Aquaro S; Bellagamba R; Boumis E; Di Perri G; Pizzi D; Antinori A; Rezza G; Perno CF
    AIDS Res Hum Retroviruses; 2007 Oct; 23(10):1296-302. PubMed ID: 17961119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selection with a peptide fusion inhibitor corresponding to the first heptad repeat of HIV-1 gp41 identifies two genetic pathways conferring cross-resistance to peptide fusion inhibitors corresponding to the first and second heptad repeats (HR1 and HR2) of gp41.
    Wang W; De Feo CJ; Zhuang M; Vassell R; Weiss CD
    J Virol; 2011 Dec; 85(24):12929-38. PubMed ID: 21994458
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Short communication: high polymorphism rates in the HR1 and HR2 gp41 and presence of primary resistance-related mutations in HIV type 1 circulating in Brazil: possible impact on enfuvirtide efficacy.
    Teixeira C; de Sá-Filho D; Alkmim W; Janini LM; Diaz RS; Komninakis S
    AIDS Res Hum Retroviruses; 2010 Mar; 26(3):307-11. PubMed ID: 20334566
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduced Susceptibility to VIRIP-Based HIV-1 Entry Inhibitors Has a High Genetic Barrier and Severe Fitness Costs.
    Müller JA; Glöckle A; Gawanbacht A; Geyer M; Münch J; Kirchhoff F
    J Virol; 2018 Sep; 92(17):. PubMed ID: 29925662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resistance of human immunodeficiency virus type 1 to a third-generation fusion inhibitor requires multiple mutations in gp41 and is accompanied by a dramatic loss of gp41 function.
    Eggink D; Bontjer I; Langedijk JP; Berkhout B; Sanders RW
    J Virol; 2011 Oct; 85(20):10785-97. PubMed ID: 21835789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIVfird: A Tool for Detection of Resistance to Fusion Inhibitor Drugs in HIV-1 Sequences.
    Barreto Vasconcelos AL; Monteiro-Cunha JP
    AIDS Res Hum Retroviruses; 2019 Oct; 35(10):941-947. PubMed ID: 31280582
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genotypic changes in human immunodeficiency virus type 1 envelope glycoproteins on treatment with the fusion inhibitor enfuvirtide and their influence on changes in drug susceptibility in vitro.
    Su C; Melby T; DeMasi R; Ravindran P; Heilek-Snyder G
    J Clin Virol; 2006 Aug; 36(4):249-57. PubMed ID: 16765082
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic evolution of gp41 reveals a highly exclusive relationship between codons 36, 38 and 43 in gp41 under long-term enfuvirtide-containing salvage regimen.
    Cabrera C; Marfil S; García E; Martinez-Picado J; Bonjoch A; Bofill M; Moreno S; Ribera E; Domingo P; Clotet B; Ruiz L
    AIDS; 2006 Oct; 20(16):2075-80. PubMed ID: 17053353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of Gp41 polymorphisms in the fusion peptide domain and T-20 (Enfuvirtide) resistance-associated regions in Korean HIV-1 isolates.
    Jang DH; Yoon CH; Choi BS; Chung YS; Kim HY; Chi SG; Kim SS
    J Korean Med Sci; 2014 Mar; 29(3):456-9. PubMed ID: 24616600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ADS-J1 inhibits HIV-1 infection and membrane fusion by targeting the highly conserved pocket in the gp41 NHR-trimer.
    Yu F; Lu L; Liu Q; Yu X; Wang L; He E; Zou P; Du L; Sanders RW; Liu S; Jiang S
    Biochim Biophys Acta; 2014 May; 1838(5):1296-305. PubMed ID: 24388952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of determinants of genotypic and phenotypic resistance to enfuvirtide in baseline and on-treatment HIV-1 isolates.
    Sista PR; Melby T; Davison D; Jin L; Mosier S; Mink M; Nelson EL; DeMasi R; Cammack N; Salgo MP; Matthews TJ; Greenberg ML
    AIDS; 2004 Sep; 18(13):1787-94. PubMed ID: 15316339
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.